$2.37
+0.04(1.72%)
Mkt Cap $212.9K
$2.19
$63.28
52-Week Range
At A Glance
1
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune d...
2
Most recently: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 15, 2026, GRI Bio, Inc. (the “Company”) was form (2026-01-16).
$212.9K
Market Cap
$5M
Revenue
-$2M
Net Income
Employees3
Fundamentals
How The Business Makes Money
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001824293
ISINUS3622AW5029
CUSIP3622AW502
Phone619 400 1170
Address2223 Avenida de la Playa, La Jolla, CA, 92037, US
SEC EDGAR